Pomalidomide in Refractory Multiple Myeloma In this segment, Noopur Raje, MD, Sagar Lonial, MD, and Ann McNeill, RN, APN, discuss the role of pomalidomide in therapy for patients with multiple myeloma, as well as the toxicities and adverse reactions associated with pomalidomide therapy. Get more expert insight, at http://www.onclive.com/insights/myeloma

Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM) Background: MM inevitably relapses and becomes refractory to treatment, representing a patient (pt) population with unmet needs. Teclistamab (JNJ-64007957) is a bispecific BCMA x CD3 […]

How is nonsecretory multiple myeloma diagnosed? Dr. Philippe Moreau discusses diagnosing multiple myeloma in a patient that is not secreting proteins but presents with CRAB symptoms. Join our online communities to begin receiving free continuing medical education (CME) credit today! Managing Myeloma: http://www.managingmyeloma.com/ Managing Hodgkin Lymphoma: http://www.managinghodgkinlymphoma.com/ Managing MDS: http://www.managingmds.com/ Managing CML: http://www.managingcml.com/ Partners in […]

Ask the Multiple Myeloma Experts Summary: The current standard of care for patients with multiple myeloma is high dose chemotherapy and an autologous stem cell transplant. Although an autologous transplant is not a cure, maintenance therapy with various drugs can control myeloma in many patients for several years. Panelists: Jens Hillengass MD, Chief of Myeloma, […]

Innovative treatment strategies for multiple myeloma Ruben Niesvizky, MD, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, comments on new developments in treatments for multiple myeloma. Novel immunomodulating agents such as iberdomide and other cereblon E3 ligase modulators (CELMoDs) have shown promising results and could be given in combination with other immunological therapies. In […]

Microbiomes, mice and multiple myeloma Lawrence Boise, PhD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses findings from a study on the effects of varying microbiomes on the rate of development of multiple myeloma (MM) in mice. This interview took place at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Peter Voorhees, MD: Understanding Your Multiple Myeloma Genetics: MCRT Charlotte 2018 The genetics of multiple myleoma is very complex, and has implications for the personalized treatment of the disease and disease prognosis. Dr Voorhees explains the different genetic abnormalities that occur in myeloma and how we can approach treatment with these in mind.

Multiple Myeloma has a low Anion Gap…Ever wonder Why? Multiple Myeloma has a low Anion Gap…Ever wonder Why?! 🧪Acid-Base Course: https://www.medicosisperfectionalis.com/products/p/acid-base-disturbances-course/ 📝 Nerve Physiology Notes: https://www.medicosisperfectionalis.com/ 🤒 Autacoids Pharmacology Course: https://www.medicosisperfectionalis.com/ ⁉️ Questions and Answers: https://www.medicosisperfectionalis.com/ 📝 Notes: https://www.medicosisperfectionalis.com/ 🗳 Complete the Survey: https://airtable.com/shrYWjvabooT7DrcG 💊🦠 Antibiotics Course: https://www.medicosisperfectionalis.com/products/courses/antibiotics/ 📊 My favorite Productivity App (Airtable): https://airtable.com/invite/r/2zH40fus/ […]

522 CHRONIC RENAL FAILURE DUE TO MULTIPLE MYELOMA HISTOLOGY ON THYROIDIZATION OF KIDNEY : http://library.med.utah.edu/WebPath/RENAHTML/RENAL108.html http://www.google.ca/imgres?q=multiple+myeloma+and+chronic+renal+failure&um=1&hl=en&sa=N&tbo=d&biw=1197&bih=684&tbm=isch&tbnid=1Yj3H-JuxyUG3M:&imgrefurl=http://www.studyblue.com/notes/note/n/l74-chronic-renal-failure-pathology/deck/793137&docid=FZTgnDR4Kq7q3M&imgurl=http://test.classconnection.s3.amazonaws.com/434/flashcards/174434/jpg/cast_nephropathy_of_multiple_myeloma.jpg&w=480&h=360&ei=Ky6tUK3zNKHL2QXruoHoBQ&zoom=1&iact=rc&dur=325&sig=107926594632941335121&page=1&tbnh=134&tbnw=187&start=0&ndsp=25&ved=1t:429,r:3,s:0,i:94&tx=80&ty=47, http://en.wikipedia.org/wiki/Interstitial_nephritis, http://en.wikipedia.org/wiki/Acute_uric_acid_nephropathy, http://en.wikipedia.org/wiki/Renal_papillary_necrosis

Optimizing treatment sequencing in multiple myeloma: daratumumab upfront versus subsequent lines Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses the findings of a study investigating optimal treatment sequencing in multiple myeloma. With the available options for treatment expanding rapidly, determining the best strategies for upfront treatment and subsequent lines of therapy is of critical importance. […]